<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6575">
  <stage>Registered</stage>
  <submitdate>19/06/2017</submitdate>
  <approvaldate>19/06/2017</approvaldate>
  <nctid>NCT03199001</nctid>
  <trial_identification>
    <studytitle>Native T1 Mapping by Cardiovascular Magnetic Resonance Imaging in Rare Diseases</studytitle>
    <scientifictitle>Native T1 Mapping by Cardiovascular Magnetic Resonance Imaging in Rare Diseases- A New Method to Improve Patient Care</scientifictitle>
    <utrn />
    <trialacronym>FABRY400</trialacronym>
    <secondaryid>14/0354</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Fabry Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions />
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Presence of storage in Fabry cardiomyopathy - Presence or absence of storage (measured in milliseconds) by T1 mapping by CMR</outcome>
      <timepoint>1 hour</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Presence of inflammation in Fabry cardiomyopathy - Presence or absence of inflammation (measured in milliseconds) by T2 mapping by CMR</outcome>
      <timepoint>1 hour</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in storage measure - Change in storage measure (measured in milliseconds) by T1 mapping by CMR</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Gene-positive Fabry Disease

          -  Male or female

          -  Age at least 9 years</inclusivecriteria>
    <inclusiveminage>9</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Any absolute contraindication to CMR

          -  Pregnancy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>19/02/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>400</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>19/02/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>University of Sydney - Sydney</hospital>
    <postcode> - Sydney</postcode>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>University College, London</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>University Hospital Birmingham</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>University of Sydney</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Fabry Disease (FD) is a rare, X-linked lysosomal storage disorder leading to left ventricular
      hypertrophy, myocardial fibrosis, arrhythmia and heart failure. Cardiac involvement is the
      leading cause of death in FD. Treatment with enzyme replacement therapy is expensive, may be
      poorly targeted and there are difficulties in early detection and disease monitoring. T1
      mapping signal change is a potential remarkable biomarker for FD.

      Fabry400 is a multicentre study aiming to understand the biology of Fabry Disease and its
      relationship to non-invasive multi parametric mapping by CMR.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03199001</trialwebsite>
    <publication>Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G, Fontana M, Maestrini V, Flett AS, Robson MD, Lachmann RH, Murphy E, Mehta A, Hughes D, Neubauer S, Elliott PM, Moon JC. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging. 2013 May 1;6(3):392-8. doi: 10.1161/CIRCIMAGING.112.000070. Epub 2013 Apr 5.
Pica S, Sado DM, Maestrini V, Fontana M, White SK, Treibel T, Captur G, Anderson S, Piechnik SK, Robson MD, Lachmann RH, Murphy E, Mehta A, Hughes D, Kellman P, Elliott PM, Herrey AS, Moon JC. Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2014 Dec 5;16:99. doi: 10.1186/s12968-014-0099-4.
Nappi C, Altiero M, Imbriaco M, Nicolai E, Giudice CA, Aiello M, Diomiaiuti CT, Pisani A, Spinelli L, Cuocolo A. First experience of simultaneous PET/MRI for the early detection of cardiac involvement in patients with Anderson-Fabry disease. Eur J Nucl Med Mol Imaging. 2015 Jun;42(7):1025-31. doi: 10.1007/s00259-015-3036-3. Epub 2015 Mar 26.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>James Moon, MD</name>
      <address />
      <phone />
      <fax />
      <email>j.moon@ucl.ac.uk</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>